Abstract
Asthma is a common chronic inflammatory disorder that causes reversible obstruction in the airways leading to hard breath and difficulty in the doing of the daily activities. It’s multifactorial disorder effected by many biomarkers, one of this biomarkers is Gal -3. The present study aims to assessment of Galectin-3 as new biomarker and its role on developing of the asthma. In this research, a comparison was made between a group of asthmatic patients and a control group, with a total of fifty individuals in each category. Among the asthmatic patients, fifty appeared to be in good health, and their conditions were confirmed through consultations with specialists at Merjan Teaching Hospital in Hilla, Iraq. Upon examining the data, it was found that the serum Gal-3 levels in asthmatic patients were notably lower than those in the control group. Furthermore, it was observed that individuals with severe asthma had even lower levels of Gal-3 compared to those with mild asthma.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
